Literature DB >> 8771075

Tetrabenazine as a cause of neuroleptic malignant syndrome.

M Ossemann, C J Sindic, C Laterre.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8771075     DOI： 10.1002/mds.870110118

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


× No keyword cloud information.
  6 in total

1.  Severe hyperthermia during tetrabenazine therapy for tardive dyskinesia.

Authors:  E Stevens; A Roman; M Houa; D Razavi; N Jaspar
Journal:  Intensive Care Med       Date:  1998-04       Impact factor: 17.440

Review 2.  Cervical dystonia pathophysiology and treatment options.

Authors:  M Velickovic; R Benabou; M F Brin
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 3.  Tourette's syndrome and role of tetrabenazine: review and personal experience.

Authors:  Mauro Porta; Marco Sassi; Mario Cavallazzi; Maurizio Fornari; Arianna Brambilla; Domenico Servello
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

Review 4.  Symptomatic treatment of Huntington disease.

Authors:  Octavian R Adam; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

5.  Risk of Neuroleptic Malignant Syndrome with Vesicular Monoamine Transporter Inhibitors.

Authors:  Stanley N Caroff
Journal:  Clin Psychopharmacol Neurosci       Date:  2020-05-31       Impact factor: 2.582

6.  Tetrabenazine in the treatment of Huntington's disease.

Authors:  Diana Paleacu
Journal:  Neuropsychiatr Dis Treat       Date:  2007       Impact factor: 2.570
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.